FDA May Grant Advantages For Vertex's Telaprevir Over Merck's Boceprevir
This article was originally published in The Pink Sheet Daily
Executive Summary
Heading into an Antiviral Products Advisory Committee review April 28, FDA briefing documents indicate some strengths for Vertex's HCV drug over Merck's boceprevir.
You may also be interested in...
Vertex's Telaprevir Slides By Advisory Committee, But Panelists Want Limits On Some Patients
While the committee unanimously endorsed the protease inhibitor for approval, some panelists question whether there is sufficient data to support response-guided therapy for prior-relapse patients.
Vertex's Telaprevir Slides By Advisory Committee, But Panelists Want Limits On Some Patients
While the committee unanimously endorsed the protease inhibitor for approval, some panelists question whether there is sufficient data to support response-guided therapy for prior-relapse patients.
Advisory Panel To Consider Scope Of Indication For Merck's Hep C Drug Boceprevir
Agency asks about data on prior null responders and about anemia effects. Merck has proposed a safety monitoring program while avoiding REMS terminology.